Posted by Michael Wonder on 29 Jul 2024
CStone announces European Commission approval of Sugemalimab (Cejemly) as first-line treatment for non-small cell lung cancer
26 July 2024 - The European Commission approval is based on the results of GEMSTONE-302 Phase 3 trial, which demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival and overall survival in treatment naive patients with metastatic non-small cell lung cancer.
CStone Pharmaceuticals today announced that the European Commission has approved sugemalimab (Cejemly) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations.
